KEYNOTE-522: Neoadjuvant pembro chemo vs placebo chemo, followed by adjuvant pembro vs placebo for early TNBC

Bookmark and Share
Published: 19 Dec 2019
Views: 624
Dr Jay Andersen - Compass Oncology West Cancer Center, Tigard, USA

Dr Jay Andersen speaks to ecancer at the 2019 San Antonio Breast Cancer Symposium about the results from the KEYNOTE-522 study analysing neoadjuvant pembrolizumab chemotherapy vs placebo chemotherapy, followed by adjuvant pembrolizumab vs placebo for early TNBC.

He reports that the primary endpoint of pathological complete response was measured, with it increasing from 51% to 64%.

Dr Andersen also reports that from early data an event free survival benefit could be seen with an increase from 85% to 91%.